Phase 1 Prader-Willi syndrome (PWS) PWS is caused by three types of abnormality in chromosome 15 at a prevalence rate of 1:11,000 to 1:22,000. The defining feature of PWS is food-seeking behaviour due to constant hunger. Hyperphagia and obesity are one of the main burdens in PWS and obesity is linked to increased morbidity and mortality. Clinical Trials

1 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–1 of 1 trials

Recruiting

Phase 1

A study on the satiety effect of Caralluma fimbriata extract for people with Prader - Willi syndrome (PWS).”

Prader-Willi syndrome (PWS) PWS is caused by three types of abnormality in chromosome 15 at a prevalence rate of 1:11,000 to 1:22,000. The defining feature of PWS is food-seeking behaviour due to constant hunger. Hyperphagia and obesity are one of the main burdens in PWS and obesity is linked to increased morbidity and mortality.

Victoria University16 enrolled1 locationACTRN12611000334909